IP Library Granted Patent US 8,598,118
Granted Patent B2
US 8,598,118 · App. 13/768,497 · Granted Dec 3, 2013

Hepatocyte growth factor mimics as therapeutic agents

Inventors: Joseph W. Harding (Pullman, WA); John W. Wright (Pullman, WA); Caroline C. Benoist (Nashville, TN); Leen H. Kawas (Pullman, WA); Gary A. Wayman (Pullman, WA)
Assignee: Washington State University
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,598,118
App. No.
13/768,497
Granted
Dec 3, 2013
Kind
B2
Abstract

Small molecule, peptidic hepatocyte growth factors mimics, which act as both mimetics and antagonists, have been generated. These molecules have been shown or predicted to have therapeutic potential for numerous pathologies including dementia, neurodegenerative disease, diabetes and metabolic syndrome, cancer, and defective wound healing.

Claims (18)

1. A hepatocyte growth factor (HGF) mimic having the general formula:

where

R 1 is an amino acid, said amino acid being selected from the group consisting of tyrosine, phenylalanine, aspartic acid, arginine, isoleucine, serine, histidine, glycine, cysteine, methionine, tryptophan, lysine, norvaline, ornithine, and s-benzyl cysteine;

R 2 is an amino acid selected from the group selected from the group consisting of tyrosine, phenylalanine, aspartic acid, arginine, isoleucine, serine, histidine, glycine, cysteine, methionine, tryptophan, lysine and valine;

R 3 is isoleucine; and

n ranges from 3-6; and

wherein covalent bonds 1, 2 and 3 are selected from the group consisting of peptide bonds or reduced peptide bonds.

2. N-hexanoic-L-tyrosine-L-isoleucine-(6)-aminohexanoic amide.

3. A composition, comprising:

at least one hepatocyte growth factor (HGF) mimic having the general formula:

where

R 1 is an amino acid selected from tyrosine, phenylalanine, aspartic acid, arginine, isoleucine, serine, histidine, glycine, cysteine, methionine, tryptophan, lysine, norvaline, ornithine, and s-benzyl cysteine;

R 2 is an amino acid selected from the group selected from the group consisting of tyrosine, phenylalanine, aspartic acid, arginine, isoleucine, serine, histidine, glycine, cysteine, methionine, tryptophan, lysine and valine;

R 3 is isoleucine; and

n ranges from 3-6; and

wherein covalent bonds 1, 2 and 3 are selected from the group consisting of peptide bonds or reduced peptide bonds; and

a carrier, said HGF mimic being dissolved or distributed in said carrier.

4. A composition comprising N-hexanoic-L-tyrosine-L-isoleucine-(6)-aminohexanoic amide and a carrier, said N-hexanoic-L-tyrosine-L-isoleucine-(6)-aminohexanoic amide being dissolved or distributed in said carrier.

Assignments (2)
CONFIRMATORY LICENSE Recorded Jan 4, 2017
From: WASHINGTON STATE UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 041239/0782 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 18, 2013
From: HARDING, JOSEPH W.; WRIGHT, JOHN W.; BENOIST, CAROLINE C.; KAWAS, LEEN H.; WAYMAN, GARY A.
To: WASHINGTON STATE UNIVERSITY
Reel/Frame 029822/0178 →
Continuity (4)
Continuation PCTUS2012031815 · Apr 2, 2012
Provisional Application 61471122 · Apr 2, 2011
Provisional Application 61471124 · Apr 2, 2011
Related Publication 20130165392A1 · Jun 27, 2013